MPM Capital is a biotechnology investment firm, recently raised US$850 million for its Oncology Impact Fund 2, meant to further research by companies trying to come up with cures for cancer.
Out of this total, the bulk of it, some US$650 million, were from clients of UBS global wealth management.
The amount raised for OIF2 makes it the largest dedicated impact investment fund in biotech history.
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
